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Macrophage-derived foam cells are key regulators of atherogenesis. They accumulate in atherosclerotic 
plaques and support inflammatory processes by producing cytokines and chemokines. Identifying 
factors that regulate macrophage lipid uptake may reveal therapeutic targets for coronary artery 
disease (CAD). Here, we establish a high-throughput screening workflow to systematically identify 
genes that impact the uptake of DiI-labeled low-density lipoprotein (LDL) into monocyte-derived 
primary human macrophages. For this, monocytes isolated from peripheral blood were seeded onto 
384-well plates, solid-phase transfected with siRNAs, differentiated in vitro into macrophages, and 
LDL-uptake per cell was measured by automated microscopy and quantitative image analysis. We 
applied this workflow to study how silencing of 89 genes impacts LDL-uptake into cells from 16 patients 
with CAD and 16 age-matched controls. Silencing of four novel genes (APOC1, CMTM6, FABP4, WBP5) 
reduced macrophage LDL-uptake. Additionally, knockdown of the chemokine receptor CXCR4 reduced 
LDL-uptake, most likely through a G-protein coupled mechanism that involves the CXCR4 ligand 
macrophage-induced factor (MIF), but is independent of CXCL12. We introduce a high-throughput 
strategy to systematically study gene function directly in primary CAD-patient cells. Our results propose 
a function for the MIF/CXCR4 signaling pathway, as well as several novel candidate genes impacting 
lipid uptake into human macrophages.
Coronary artery disease (CAD) is an inflammatory disease of the arterial vessel wall and underlies myocardial 
infarction as the most common cause of death worldwide1. During atherogenesis, vascular microlesions increase 
endothelial permeability for low-density lipoprotein (LDL)-cholesterol. LDL retained in the arterial vessel wall 
can be oxidized, thereby enhancing migration of monocytes from the blood into the subendothelial space. Uptake 
of LDL by monocyte-derived macrophages contributes to foam cell formation and secretion of cytokines and 
chemokines. This attracts further immune and vascular smooth muscle cells, leading to sustained inflammation 
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and a progression of fatty streaks to irreversible alterations in the arterial wall, which constitutes the atheroscle-
rotic plaque. Over time, this lesion may become instable, rupture, and lead to platelet thrombus formation and 
ultimately myocardial infarction2,3.
Foam cells are the consequence of an imbalanced lipid uptake versus efflux in macrophages. Lipid uptake 
from native or modified LDL is mediated by the LDL-receptor, or scavenger receptors such as CD36 and SR-A, 
respectively, with minor fractions entering cells through additional mechanisms4,5. The transformation of 
monocyte-derived macrophages into foam cells is a key event during plaque formation: first, foam cells induce 
inflammation through release of a variety of cytokines and chemoattractants; second, foam cells maintain inflam-
mation in the plaque through undergoing apoptosis, which triggers further pro-inflammatory processes; and 
third, apoptotic foam cells constitute the physical center of the plaque that critically impacts plaque progres-
sion, destabilization, and rupture6. Thus, pharmacological strategies that suppress foam cell formation are highly 
sought after for the prevention or treatment of CAD7,8.
Here, we establish a high-throughput screening workflow to systematically study the impact of siRNA-induced 
loss-of-function of candidate genes on LDL-uptake into monocyte-derived macrophages from CAD patients and 
controls. We propose several novel candidate genes and the MIF/CXCR4 signaling pathway as likely functional 
regulators of foam cell formation in humans.
Results
Quantifying the functional impact of candidate gene knock-down on foam cell formation 
from primary human monocyte-derived macrophages. To systematically study the impact of mul-
tiple genes on foam cell formation in parallel, we established a workflow that enabled parallelized RNA inter-
ference (RNAi), automated microscopic image acquisition, and quantitative phenotypic analyses from primary 
blood monocyte-derived macrophages at the level of individual cells. To this end, we optimized technology for 
reverse siRNA transfection from “ready to transfect” multi-well plates9 for being suitable to study primary human 
blood-derived cells (Fig. 1a and Methods). For solid-phase reverse siRNA transfection, CD14+ monocytes were 
isolated from peripheral blood of healthy or diseased donors, seeded at a density of 20,000–25,000 cells/well 
on 384-well plates, and differentiated with macrophage colony-stimulating factor (MCSF) prior to realization 
of cell-based assays, automated microscopy and quantitative image analysis. A fluorescent-labeled siRNA con-
firmed that through this strategy nearly 100% of seeded cells could be successfully siRNA-transfected (Fig. 1b). 
Differentiation from monocytes towards macrophages followed a protocol we and others have described previ-
ously10,11 and was monitored with an antibody against CD68 (Fig. 1c). Out of four assays we had described earlier 
as suited for monitoring lipid accumulation in cells under a high-throughput setting12,13 and that are in principle 
amenable also to macrophages [including lipid droplet formation (using Oil Red O); estimation of cellular cho-
lesterol content (using filipin); and determining cellular uptake of either native or oxidized fluorescent-labeled 
low-density lipoprotein (DiI-LDL and DiI-oxLDL) (Fig. S1)], we chose to optimize measuring DiI-LDL uptake 
for a proof-of-concept high-throughput screening study in primary patient-derived macrophages. A significant 
reduction in LDL-uptake relative to controls could be quantified when cells were transfected with siRNAs target-
ing positive controls such as the LDL-receptor (LDLR), the cholesterol scavenger receptor CD36, or the MCSF 
receptor (CSF1R)5 (Fig. 1d–g).
RNAi-screening of genes induced during foam cell formation identifies novel regulators of 
macrophage LDL-uptake. With the aim to identify novel regulators of LDL-uptake into monocyte-derived 
macrophages that might serve as therapeutic targets for CAD, we applied our platform to conduct a sys-
tematic RNAi-screen. We focused on a set of 89 genes which have been described earlier to be human 
macrophage-expressed genes that change expression in response to lipid loading10,14 (Table S1; see Methods for 
details on candidate gene selection). Primary blood-derived monocytes were obtained from 16 CAD patients and 
16 healthy control individuals. CAD patients tended to be older and more likely to be hypertensive or diabetic, yet 
no differences were seen regarding a diagnosis of hyperlipidemia, smoking, or family history for cardiovascular 
disease (see Table S2 for detailed participant characteristics). A primary screen was conducted in cells from 6 
patients/controls, a replication screen in cells from 10 patients/controls. Cells were solid-phase reverse siRNA 
transfected, differentiated towards macrophages, assayed for DiI-LDL uptake, and image acquisition and quanti-
tative analysis was performed.
For seven of the 89 genes studied, siRNA knockdown caused significant changes in DiI-LDL uptake dur-
ing the primary screen (Table 1; see Supplemental Data for full screening results). Specifically, knockdown of 
five genes (ALDH1A2, APOC1, CMTM6, FABP4 and WBP5) was found to significantly downregulate DiI-LDL 
uptake, whereas individual siRNAs against two genes (EPHX1 and ZYX) appeared to increase DiI-LDL uptake 
into monocyte-derived macrophages. Of these seven putative novel effector genes, four genes, APOC1, CMTM6, 
FABP4 and WBP5, could be confirmed with ≥2 siRNAs/gene as novel regulators of LDL-uptake into mac-
rophages also in the independent replication screen (Table 1, Fig. 2, Fig. S2). Interestingly, knockdown of WBP5 
reduced LDL-uptake more strongly in macrophages derived from the CAD patients than in healthy controls 
(Supplemental Data).
RNAi delineates a role for MIF/CXCR4 signaling during foam cell formation. In addition to screening 
for novel modifiers of foam cell formation, we further wanted to test whether systematic analyses in human 
monocyte-derived macrophages on our platform could help to shed light on known pathways of foam cell regula-
tion. For this, we chose to investigate the roles of CXCR4 and CXCR7 in this process. Both proteins are chemok-
ine receptors that previous studies, predominantly from mice, have proposed as relevant for lipid accumulation 
in macrophages, atherosclerosis and CAD, although the mechanisms remain unclear15. In our screening system, 
knockdown of CXCR4 strongly reduced DiI-LDL uptake, while silencing of CXCR7 did not impact this process 
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Figure 1. Microscope-based screening platform for solid-phase siRNA-transfection and functional analyses 
in primary human monocyte-derived macrophages. (a) Workflow illustrating the experimental setup: Blood 
sampling, monocyte isolation and seeding on siRNA-coated plates, monocyte-macrophage differentiation 
and solid-phase siRNA transfection, functional assays, image acquisition and analysis. (b,c) Representative 
images reflecting siRNA transfection efficiency as monitored with Cy3-labelled non-silencing control-siRNA 
(b, red) and macrophage marker CD68 (c, green) in monocyte-derived macrophages three days after siRNA 
transfection. (d) Representative images of DiI-LDL signals in cells transfected with either control siRNA or 
siRNA against CSF1R. (e,f) Relative DiI signal intensities in macrophages from 6 healthy individuals treated 
with control or CSF1R-siRNA as measured through quantitative image analysis. Each dot in (e) indicates the 
mean cellular DiI signal intensity per 1 frame from 15 technical replicates per individual (i.e., independent wells 
of a plate). (f) Shows change in DiI signal relative to negative control in percent (±s.d.). (g) Mean±s.d. relative 
change in DiI signal compared to negative control in percent for siRNAs against LDLR and CD36. Macrophages 
from 6 healthy individuals were used with 12 technical replicates per individual. P values were calculated with 
Bonferroni corrected unpaired two-tailed t-test. **P < 0.001; ***P < 0.0001.
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(Fig. 3a,b). This suggests that, at least in vitro, the relative contribution of CXCR4 to foam cell formation from 
human monocyte-derived macrophages exceeds that of CXCR7.
In order to gain insights into the underlying mechanisms, we systematically studied the relevance of different 
components of the CXCR4 signaling pathway on DiI-LDL uptake. For this, we first silenced the CXCR4 ligands 
CXCL12 and MIF16. Silencing of CXCL12 did not impact DiI-LDL uptake in our system. However, knockdown of 
MIF reduced DiI-LDL uptake into human monocyte-derived macrophages (Fig. 3c). This suggests that CXCR4 
impacts foam cell formation via the MIF signaling axis rather than via CXCL12.
To further validate these findings, we incubated monocyte-derived macrophages with MIF and CXCL12 
proteins for 8 and 24 hours, respectively, and measured DiI-LDL uptake. Consistent with the findings upon 
knockdown, addition of CXCL12 protein did not affect DiI-LDL uptake. Conversely, addition of MIF signifi-
cantly stimulated LDL uptake in human monocyte-derived macrophages at both time points measured (Fig. 3d). 
To confirm that the impact on LDL-uptake was indeed conveyed by the interplay of MIF with CXCR4, we 
blocked interaction of MIF with CXCR4 using the compound AMD3100 (1-[4-(1,4,8,11-Tetrazacyclotetradec-
1-ylmethyl)phenyl]methyl}-1,4,8,11-tetrazacyclo-tetradecan, Plerixafor), a clinically-approved specific inhibitor 
of ligand binding to CXCR417. While AMD3100 did not significantly impact DiI-LDL uptake either alone or 
in combination with CXCL12, it completely reverted the MIF-induced increase in DiI-LDL uptake (Fig. 3d). 
Consistent with MIF modulating DiI-LDL uptake through CXCR4, silencing of CXCR4 completely overruled 
upregulation of DiI-uptake by MIF protein (Fig. 3e). Since CXCR4 is a G-protein coupled receptor (GPCR), we 
speculated that CXCR4 might impact foam cell formation via a G-protein mediated mechanism. Indeed, incuba-
tion of human monocyte-derived macrophages with GTP-signaling inhibiting pertussis toxin for 24 hours fully 
abrogated the LDL-increasing effect of MIF on CXCR4 (Fig. 3f). Taken together, these results propose a role for 
the MIF/CXCR4 signaling pathway in the transformation of human monocyte-derived macrophages to foam 
cells. They further suggest that blocking MIF-CXCR4 interaction or GTP-mediated downstream signaling could 
be promising strategies to reduce lipid accumulation in macrophages as an important driver of atherosclerotic 
plaque formation.
Discussion
Here we introduce a novel platform to systematically conduct RNAi-screens in human primary monocyte-derived 
macrophages. Our platform is based on the parallelized solid-phase reverse siRNA transfection of monocytes iso-
lated from peripheral human blood, functional assays in monocyte-derived macrophages, automated microscopy, 
and quantitative image analysis. To demonstrate applicability of this platform, we conduct an RNAi-screen to 
identify regulators of macrophage LDL-uptake among 89 genes that were previously reported as differentially 
regulated in foam cells. We show that knockdown of APOC1, CMTM6, FABP4 and WBP5 reduces the uptake 
of fluorescent-labeled LDL into macrophages from 32 individuals (16 CAD patients and 16 healthy controls), 
suggesting that a reduced function of these genes could negatively impact foam cell formation. Furthermore, we 
substantiate evidence for CXCR4 as a critical regulator during atherogenesis by proposing a role for the MIF/
CXCR4 signaling pathway on macrophage LDL-uptake that is potentially amenable to therapeutic intervention.
Macrophages constitute a critical cell type during development and destabilization of atherosclerotic 
plaques5–8,18. By internalizing lipids and transforming into foam cells, they promote the progression of an ather-
osclerotic lesion and initiate and maintain inflammatory processes. While de-differentiated human macrophage 
model cell lines such as THP-1 cells are now increasingly used in screening settings, most insights into mac-
rophage biology and their role in disease are derived from animal models. Human primary monocyte-derived 
macrophages without further differentiation have, to the best of our knowledge, thus far not been analyzed in 
systematic RNAi-screens, although the opportunity to analyze primary cells derived directly from peripheral 
blood of patients may offer significant advantages.
In our study, we queried for genes that modulate LDL-uptake into monocyte-derived macrophages, and thus 
could potentially serve as therapeutic targets for enabling cardiovascular therapies. We followed a paradigm that 
we had successfully applied earlier12,13 and analyzed a set of genes that had previously been identified as differ-
entially regulated at the transcriptional level during foam cell formation for an impact on the internalization of 
fluorescent-labelled LDL into cells, a critical constituent during foam cell formation from macrophages5. In two 
independent screens in cells from both, CAD patients and controls, we identified four genes as consistent modu-
lators of macrophage DiI-LDL uptake: APOC1, CMTM6, FABP4 and WBP5.
APOC1 encodes apolipoprotein C-I, a protein with central functions in lipoprotein metabolism. APOC1 
is part of the TOMM40/APOE/APOC1 gene cluster on chromosome 19q13 that has been associated through 
GWAS via rare and common alleles with plasma lipid levels and carotid intima media thickness among oth-
ers19,20. Various studies have investigated the role of APOC1 in the regulation of plasma lipid levels21,22, and ele-
vated APOC1 plasma levels have been proposed as potentially aggravating CAD and myocardial infraction in 
mice and humans23,24. APOC1 is highly expressed during monocyte-to-macrophage differentiation25 and mod-
ulates phospholipid and cholesterol efflux from macrophages23. That knockdown of APOC1 modulates DiI-LDL 
uptake supports our earlier observations from HeLa cells where independent APOC1 siRNAs also tended to lower 
LDL-internalization, although in our earlier study they had failed to meet our stringent significance thresholds13. 
Future studies will need to determine the exact mechanisms how APOC1 impacts macrophages.
Fatty acid binding protein-4 (FABP4) is a small cytoplasmic lipid chaperone that binds long-chain fatty acids 
and regulates lipid-induced macrophage endoplasmic reticulum (ER) stress26,27. Elevated FABP4 levels have been 
linked to a modestly higher risk of heart failure, and sudden cardiac death28,29, and a variant near FABP4 was 
proposed to reduce the risk of cardiovascular incidents and increase plaque stability30,31. Genetic or chemical 
inhibition of FABP4 alleviates macrophage ER stress and protects against atherosclerosis in an animal model27. 
Based on our screening results it is tempting to speculate that at least part of the anti-atherogenic effects upon 
FABP4 inhibition are conveyed through reduction of lipid accumulation in macrophages.
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Gene siRNA ID
Primary Screen Replication Screen
Mean 
Md(C)
Mean 
Md(P)
Mean 
Md(C + P)
Mean 
Md(C)
Mean 
Md(P)
Mean 
Md(C + P)
ALDH1A2
s16908 0.9 0.3 0.6 n.a. n.a. n.a.
s225046 −0.2 −1.2 −0.5 −1.2 −1.8 −1.4
s16907 0.8 −0.9 −0.3 −0.8 −0.9 −0.8
APOC1**
s194287 −1.4 −0.6 −1.2 −1.1 −1.5 −1.1
s1481 0.1 0.1 0.1 n.a. n.a. n.a.
s1482 −0.5 −0.8 −0.7 −0.9 −1.5 −1.0
CMTM6**
s29750 −1.0 0.0 −0.2 −1.0 −1.5 −1.2
s226803 −0.7 −0.6 −0.6 −0.9 −1.6 −1.1
s29749 0.3 0.3 0.3 n.a. n.a. n.a.
EPHX1
s4750 −0.1 1.5 0.2 −0.9 −1.6 −1.1
s4749 0.5 0.9 0.7 −0.6 −0.4 −0.5
s4751 −0.1 −0.2 −0.2 n.a. n.a. n.a.
FABP4**
s4965 0.0 0.5 0.2 n.a. n.a. n.a.
s4966 −3.1 −2.6 −2.9 −1.2 −2.0 −1.3
s4964 −0.6 −1.2 −1.0 −0.7 −1.3 −0.9
WBP5**
s27638 −0.8 0.2 −0.3 −1.1 −2.2 −1.4
s27637 −0.3 0.3 −0.1 n.a. n.a. n.a.
s27639 −1.1 −0.4 −0.7 −0.9 −1.9 −1.1
ZYX
s15351 −0.1 0.2 −0.1 n.a. n.a. n.a.
s15352 0.8 −0.1 0.1 −0.4 −0.3 −0.3
s224804 1.6 0.6 0.8 −0.5 −0.5 −0.5
Table 1. Genes identified as functional regulators of DiI-LDL uptake into cultured primary human monocyte-
derived macrophages. The impact on DiI-LDL uptake upon candidate gene knockdown was analyzed with 
3 independent siRNAs/gene. SiRNAs meeting significance criteria (z-score/Deviation >|1|) are displayed in 
bold as mean medians of deviations (Md). Genes with ≥2 significant siRNAs validated in replication screen are 
highlighted by**. Negative values indicate reduction in DiI-LDL uptake relative to control-siRNA transfected 
cells. C, control individuals; P, coronary-artery disease patients; column Md(C + P) indicates means across 
patients and control individuals in this study. n.a., not analyzed.
Figure 2. Knockdown of APOC1, CMTM6, FABP4 and WBP5 reduces DiI-LDL uptake into primary human 
monocyte-derived macrophages. Bars reflect mean ± S.D relative change in cellular DiI-LDL fluorescence 
signal intensities as determined from cultured primary human monocyte-derived macrophages during the 
replication screen. Cells were solid-phase transfected with siRNAs against indicated genes (2 independent 
siRNAs/gene), and DiI-LDL uptake was measured relative to control siRNA treated cells with 1.0 being the 
mean intensity of all negative control wells for each plate. Shown are results from cells of 10 healthy individuals 
(grey) and 10 patients with coronary artery disease (orange). To determine significance, deviation values 
(Dev; see Methods) were calculated for each siRNA tested in each individual relative to the mean intensity 
of respective negative control wells, and the median deviation was calculated for the control group (Md(C)), 
the patient group (Md(P)), and the combination of both groups (Md(C + P)) separately. Finally, the mean 
median deviation shown was calculated from the median deviation of results from three technical replicates per 
individual (i.e, three independent parallel analyses of cells isolated from the same blood draw). **Dev <−1.0 
for at least 2 siRNAs in 1 group (controls, patients, controls + patients). For full siRNA screening results from 
primary and replication screens, see Supplemental Data.
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Figure 3. The MIF-CXCR4 signaling axis regulates DiI-LDL uptake into primary human monocyte-derived 
macrophages. (a) Relative change in DiI signal intensity compared to negative control (in percent) in macrophages 
treated with siRNAs against CXCR4 or CXCR7 (n = 5). (b) Representative images of DiI-LDL signal in 
macrophages treated with CXCR4- or control-siRNA. (c) Relative change in DiI signal intensity compared to 
negative control in per cent in macrophages treated with siRNAs against CXCL12 or MIF (n = 3). (d) Relative 
change in DiI fluorescence intensity compared to negative control (untreated cells) after stimulation with either 
AMD3100 (AMD) alone for 8 or 24 hours, or CXCL12 (1 μg/ml) or MIF (1 μg/ml) for 8 or 24 hours in the absence 
or presence of AMD (n = 3). (e) Relative change in DiI fluorescence intensity compared to negative control siRNA 
after treatment with CXCR4-siRNA in the absence or the presence of MIF (1 μg/ml) for 24 hours. (f) Relative 
change in DiI fluorescence intensity compared to negative control (untreated cells) after stimulation with MIF 
(1 μg/ml) in the absence or presence of pertussis toxin (250 ng/ml) for 24 hours (n = 3). P-values were calculated 
with unpaired, two-tailed t-test followed by a post-hoc Dunn’s multiple comparison test. ***P < 0.0001.
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Much less is known about the two remaining newly identified regulators of macrophage LDL-uptake, WBP5 
(aka: TCEAL9) and CMTM6. WBP5 encodes the transcription elongation factor A like 9, which binds polyproline 
ligands and contains a WW domain that mediates protein-protein interaction32. Interestingly, while knockdown 
of WBP5 reduced DiI-LDL uptake in macrophages from both, CAD patients and healthy controls, this reduction 
was considerably more pronounced in patient cells, assuming a potential relevance for this gene in CAD patho-
genesis. CMTM6 is part of a little characterized chemokine-like factor gene superfamily. It is widely expressed 
across tissues, with high expression levels in monocytes33. Importantly, rs7640978 near CMTM6 has been iden-
tified as associated with LDL-cholesterol and total cholesterol through the Global Lipids Genetics Consortium34. 
Our finding that reduction of CMTM6 in macrophages reduces LDL-uptake adds support that CMTM6 is the 
causal gene conferring the lipid association at this GWAS locus, and that inhibition of CMTM6 might be cardio-
protective. Most interestingly, two very recent studies have identified CMTM6 as a binder and master regulator of 
cell-surface abundance of the immune checkpoint regulator PD-L1, expanding a putative therapeutic application 
for this gene to immuno-oncology35,36. Further studies will be required to elucidate the exact mechanisms how 
the newly-identified regulators impact macrophage biology.
With the aim to demonstrate the applicability of our platform towards an improved understanding of the 
molecular processes leading to foam cell formation, we further studied the role of the chemokine receptor CXCR4 
and its ligands in this process. CXCR4 has been described earlier as upregulated during macrophage foam cell 
formation10,14 and regulating clathrin-mediated endocytosis of acetylated LDL37. Consistent with a function dur-
ing foam cell formation, we found here that knockdown of CXCR4, but not CXCR7, reduces LDL-uptake into 
monocyte-derived human macrophages under our settings. This observation is interesting since CXCR4 as well 
as the CXCR4 ligands CXCL12 and MIF have been implicated in atherogenesis and CAD: For CXCR4 itself, 
recent regression analyses have shown an association of the common CXCR4 variant rs2322864, which reduces 
CXCR4 expression in carotid artery plaques, with increased risk for CAD in humans, and vascular CXCR4 was 
shown to reduce atherosclerosis by maintaining arterial integrity. However, it was also discussed that CXCR4 
may also confer pro-atherogenic effects in cell types distinct from neutrophils, endothelial cells or smooth 
muscle cells38. CXCL12 has been robustly associated through GWAS with CAD39, and increasing CXCL12 in 
Apoe−/− mice reduced atherosclerosis40 and the foam cell content in lesions40,41. On the other hand, MIF showed 
a pro-atherogenic role in Lldr−/− mice42. In our cell-based approach, knockdown of MIF strongly reduced, while 
exogenous addition of MIF stimulated DiI-LDL uptake into macrophages. Conversely, no such effect was found 
for either CXCL12 reduction nor addition under our experimental settings. The impact of MIF on LDL-uptake 
was dependent on CXCR4, since it was abrogated by either blocking the interaction of the two proteins via the 
compound AMD3100, or in CXCR4 knock-down cells. Further studies will need to investigate how modulation 
of MIF/CXCR4 impacts macrophage LDL-uptake and the development of CAD in vivo. Further, while our initial 
experiments with pertussis toxin indicate that G-protein signaling might play a role, the exact mechanisms how 
the MIF/CXCR4 signaling axis modulates LDL-uptake will need to be further clarified. For instance, in addition 
to receptor-mediated processes, LDL may be internalized into cells through PI3K-dependent fluid-phase pinocy-
tosis43–45. MIF induces PI3K signaling via CD74/CXCR446, and the CXCL12/CXCR4 axis was previously shown to 
increase macropinocytosis of a cell-penetrating peptide in HeLa cells47. Combined, it is thus tempting to speculate 
that MIF/CXCR4/PI3K-signaling might confer macrophage LDL-uptake through pinocytosis, a hypothesis that 
should be followed in future studies.
Our study has several limitations. First, cell culture and in vitro differentiation from monocytes on 
siRNA-arrays may remain incomplete or introduce undesired changes to macrophages that might not be 
present in vivo. We have tried to control for that by monitoring for morphology as well as the expression of 
macrophage-specific markers, but only future applications with a larger range of assays will determine by which 
the model we newly introduce here matches or differs from alternative macrophage models. And second, we can-
not exclude that the genes identified in our RNAi-screen impact LDL-uptake differently in alternative cell models, 
or influence lipid accumulation only in an indirect manner. While the gene set analyzed here had been highly 
prioritized for genes that are differentially regulated during foam cell formation, there could be interacting factors 
that might serve as the better therapeutic targets when manipulated by siRNAs or compounds. As we highlight at 
the case of CXCR4, unbiased analyses as they are now possible on our platform will help to substantiate existing 
and create new hypotheses on known and novel players of macrophage biology.
In summary, we introduce a scalable microscope-based platform for systematic functional studies in pri-
mary human monocyte-derived macrophages. We propose four genes as putative novel regulators of macrophage 
LDL-uptake that possibly directly may impact foam cell formation. Future studies will show whether the plat-
form introduced here may assist diagnosis or risk assessment in patients, and whether the genes prioritized here 
through siRNA-screening have a therapeutic potential.
Methods
Selection of candidate genes and siRNAs. For selecting a gene set of 89 candidates, genes significantly 
up- and down-regulated during foam cell formation from human macrophages were selected from two previous 
publications10,14. Cho et al.10 report data acquired from two sets of experiments in which macrophages from 
healthy individuals were exposed to oxidized LDL (oxLDL) and either stimulated with MCSF or CXCL4. For 
both conditions, the 50 most strongly up- or downregulated genes were chosen for the current study. Hägg et al.14 
report gene expression data from macrophages of 613 patients with CAD and 613 non-related controls. From this 
study, the 60 most strongly regulated genes in healthy individuals (up- or downregulation after oxLDL-stimula-
tion) and the 30 most strongly regulated genes in cells derived from CAD patients were included. Few additional 
genes were chosen from further references. In order to increase the probability to identify possible targets for 
future CAD therapies, candidates from this selection were excluded from siRNA-screening if their described pri-
mary functions related to any of the following mechanisms: (1) primary structural protein and/or responsible for 
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cell movement/attachment; (2) regulator of inflammatory response and/or part of anti-oxidative metabolism; (3) 
part of nucleic acid production, cell growth and/or proliferation; (4) ribosomal proteins; (5) pseudogene. A list of 
the 89 genes qualifying for microscope-based functional analyses is provided in Supplemental Table I.
Pre-designed 21-nt siRNAs were purchased from Ambion/Applied Biosystems (Waltham, MA, U.S.A.). To 
determine the best nucleotide sequence, all siRNA sequences suggested by Ambion were mapped to the human 
reference genome GRCh37 (Ensembl 66) using the software tool Bluegecko (J.K. Hériché, EMBL, unpublished). 
For the primary RNAi-screening, the three siRNAs targeting the largest number of transcripts were selected for 
each gene. For candidate genes qualifying for the replication screen, the two most significant siRNAs in the pri-
mary screen were analyzed.
Study participants. For all experiments, approval from the institutional ethics committee was obtained in 
advance (IRB approval # S626-2011, University of Heidelberg). All methods were performed in accordance with 
their relevant guidelines and regulations. In both, primary and replication screen, a group of patients with coro-
nary angiography-confirmed coronary artery disease was compared to age- and gender-matched healthy volun-
teers with normal coronary arteries on angiography. Males between 40 to 85 years of age were selected. Exclusion 
criteria were signs of infection, infectious and inflammatory diseases, cancer, kidney dysfunction, liver dysfunc-
tion, and neurological or psychiatric diseases, hemoglobin <10 g/dl, C-reactive protein >2 mg/dl, glomerular 
filtration rate <45 ml/min, and impaired left ventricular function. In the primary RNAi-screen, six patients and 
controls were studied, in the replication screen the number was increased to ten patients and ten controls. For 
details on the patient cohort participating in this study, see Supplemental Table II.
Monocyte isolation and macrophage differentiation. After obtaining informed consent, 400 ml 
human peripheral blood per patient was obtained. Immediately after blood draw, PMBCs were isolated using 
Histopaque (FicoLite-H, Linaris, Dossenheim, Germany), followed by negative isolation with magnetic 
beads (EasySepTM Human Monocyte Enrichment Kit, Stem Cell Technologies, Vancouver, Canada). After red 
blood cell lysis with distillated water and wash steps with 1 mM EDTA to reduce platelet and red blood cell 
contamination, monocytes were cultured in macrophage serum-free medium (Macrophage SFM (1×), liq-
uid, Invitrogen, Waltham, MA, U.S.A.) supplemented with Nutridoma SP (Roche, Indianapolis, IN, USA) in 
a cholesterol-depleted environment without the addition of bovine serum at 37 °C/5% CO2. Following estab-
lished protocols10,11, differentiation was induced by addition of 100 ng/ml recombinant human MCSF (Peprotech, 
Rocky Hill, NJ, U.S.A.) for three days. Differentiation of macrophages was confirmed by immunofluorescence 
staining for CD68 (CD68 Purified Goat poly-clonal IgG and polyclonal rabbit anti-goat IgG-FITC, Santa Cruz 
Biotechnology Inc., Dallas, TX, U.S.A.), after permeabilization with 0.1% Triton X (Sigma Aldrich, St. Louis, MO, 
U.S.A.).
Reverse siRNA transfection. 96- (High Content Imaging Glass Bottom Microplates, Corning, New 
York, NY, U.S.A.) and 384-well plates (BD Falcon 384 well, 120 µl Assay plates, San Jose, CA, U.S.A.) coated 
with siRNAs for solid phase reverse-transfection of cells were produced at the Advanced Biological Screening 
Facility, Bioquant, University of Heidelberg, as described previously9. After isolation, monocytes were distributed 
onto the prepared 96- or 384-well plates containing the dried transfection mix including the respective siRNA, 
Lipofectamine (Invitrogen, Waltham, MA, U.S.A.) and the adhesion factor fibronectine (human, Sigma-Aldrich, 
St. Louis, MO, U.S.A.).
Using a multi-channel pipette monocytes were seeded at a density of 25,000 cells/siRNA-coated 384-well for 
LDL- or oxLDL-uptake assays, and 20,000 cells/siRNA-coated 384-well for free cholesterol (FC) staining with 
Filipin or lipid droplet staining with Oil-Red(O). For siRNA-mediated down-regulation of regulators in the 
CXCR4 axis, macrophages were seeded at a density of 100,000/well. For CXCL12/MIF stimulation experiments, 
cells were seeded at a density of 25,000 cells/well.
siRNA uptake efficiency was tested by the use of Cy3-tagged control siRNA. A high percentage of Cy3-positive 
relative to Cy3-negative cells was in line with earlier findings from other cell lines and primary cells that showed 
that the solid-phase transfection protocol applied yields consistently high transfection rates9,48. Generally, the 
marginal wells of a 96- or 384-plate were not used because of plate effect errors in the marginal area. Non-silencing 
scrambled control siRNA was used as negative controls. The position of the siRNAs on the plate was randomly 
distributed across plates, and position was reshuffled for the replication screen. The following siRNAs were used 
as positive controls: CSF1R-siRNA (s3596), LDLR-siRNA (s237197), and CD36-siRNA (s2647) (all from Ambion, 
Waltham, MA, U.S.A.).
Functional assays. For analyzing DiI-LDL-uptake in primary human monocyte-derived macrophages 
we followed a protocol we had established earlier for immortalized cell lines12,13. In brief, cell culture medium 
was replaced by culture medium containing 1% HPCD ((2-Hydroxy)-β-cyclodextrin, Sigma-Aldrich, St. Louis, 
MO, U.S.A.) and cells were left at 37 °C/5%CO2 for 45 min. After washing cells with imaging solution (0.2% BSA 
(Albumin from bovine serum, Sigma-Aldrich, St. Louis, MO, U.S.A.) in MEM without phenol red, containing 
30 mM HEPES and 0.5 g/l NaHCO3 [pH 7.4] (Invitrogen, Waltham, MA, U.S.A.), 50 µg/ml DiI-LDL (Low Density 
Lipoprotein from Human Plasma, DiI complex, Invitrogen, Waltham, MA, U.S.A.) were added for 30 min at 4 °C 
and 20 min at 37 °C, followed by washing steps with imaging solution [pH 7.4], imaging solution [pH 3.5] and 
PBS, fixation with 3% Paraformaldehyde (Sigma-Aldrich, St.Louis, MO, U.S.A.), and counterstaining of nuclei 
and cytoplasm with Hoechst stain (1:1000, Hoechst Stain solution, Sigma-Aldrich, St.Louis, MO, U.S.A.) and 
deep red (1:20,000, CellMarkTM Deep Red Plasma membrane Stain, Invitrogen, Waltham, MA, U.S.A.). Identical 
steps were followed for analyzing DiI-oxLDL-uptake. For estimating free cellular cholesterol, after washing steps 
with cold PBS, cells were fixed with 3% PFA, stained with Filipin (1:20, Filipin III from Streptomyces filipinensis, 
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Sigma-Aldrich, St. Louis, MO, U.S.A.) and DRAQ5 (1:500, BioStatus limited, Shepshed, Loughborough, United 
Kingdom) for 30 minutes. Similar steps were followed when staining cells with Oil-Red O (Sigma-Aldrich, 
St.Louis, MO, U.S.A.), for which cells were counterstained with Hoechst.
CXCL12 (Peprotech, Rocky Hill, CT, U.S.A.) was used at a concentration of 1 µg/ml, MIF (provided by Prof. 
Jürgen Bernhagen, RWTH Aachen) was used at a concentration of 1 µg/ml. Macrophages were obtained (25,000 
cells/well) and incubated with BSA, CXCL12 or MIF for 8 or 24 hours. AMD3100 (Sigma-Aldrich, St. Louis, 
MO, U.S.A.) was used as an inhibitor of ligand-binding to CXCR4. For inhibition of GPCRs, differentiated mac-
rophages were incubated with pertussis toxin (250 ng/ml; 516560 Pertussis Toxin, Merck Millipore, Billerica, MA, 
U.S.A.) alone, MIF alone and in combination with MIF, or with BSA (negative controls) for 24 hours.
Automated image acquisition and analysis. Image acquisition was performed as described previously 
using an Olympus IX81 automated epifluorescence wide-field microscope and a 40× objective12,13. From each 
well, 28 non-overlapping images were taken at different positions within the well. Automated image analysis was 
performed using the software DetecTIFF, which uses an iteration algorithm to calculate signal intensity from 
multiple fluorescence channels at a single cell level49. Prior to analysis, all images were visually assessed for quality, 
and out-of-focus images as well as images with a minimal number of cells (as reflected by a median signal inten-
sity value of zero or below) were excluded.
Statistical analysis. Analysis of DiI-LDL fluorescence intensity per cell followed routines we have described 
earlier12,13,49,50. For the current study, the open-source program KNIME51 was used to establish an automated 
workflow for statistical analyses (see Supplemental Table III for analysis steps). In brief, from each image, 
DiI-LDL fluorescence intensity was quantified per cell, and intensities of all cells per image were averaged. For 
each well, the median intensity of all (up to 28) images per well was determined (Fig. SIII-I). For each technical 
replicate (i.e. plate), all intensities were normalized to the mean median intensity per well across all images from 
negative control wells (Fig. SIII-II). For siRNAs that had been analyzed in several wells of the plate, first the mean 
was calculated for each technical replicate (i.e. per plate/study participant). In a second step, these values were 
used to calculate the mean for the biological replicate for this siRNA (i.e., across multiple plates/participants) 
(Fig. SIII-III).
For statistical analysis, we further determined Deviation values and z-scores as commonly used in siRNA 
screening (Fig. SIII-IV)12,13,48,50. To counteract possible plate effects and positional effects, KNIME was pro-
grammed to calculate B-scores, reflecting a potentially more robust version of Z-scores52–54. A gene was consid-
ered a hit in the primary RNAi-screening, when in either the healthy control group, or the CAD patient group, 
or both, at least one siRNA for that gene had a Deviation value of >+1 or <−1, and another siRNA for that gene 
had a deviation of >+0.5 or <−0.5. The median of the deviation was calculated for each siRNA for control indi-
viduals (Md(C)), CAD patients (Md(P)) and the entire group comprising control individuals and CAD patients 
(Md(C + P)). In the replication screen, hit genes were defined when the deviation was >+1 or <−1 for both 
siRNAs tested. For the CXCR4 axis experiments, an unpaired two-tailed t-test was used followed by a post hoc 
Dunn’s multiple comparison test to calculate significance.
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